Loading patent…
AssigneeAlmac Discovery Limited
InventorsJames Samuel Shane ROUNTREE, Peter HEWITT, Mary Melissa MCFARLAND, Frank BURKAMP, Christina BELL, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYKA, Aaron CRANSTON, Xavier JACQ, Lauren PROCTOR
Estimating the term…
Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.
A compound, or a pharmaceutically acceptable salt, tautomer, stereoisomer or N-oxide derivative thereof, for use in therapy, wherein the compound is a compound according to formula (I):
1-(((S)-7-((R)-3-Cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-4-phenyl-5-(piperazine-1-carbonyl)pyridin-2(1H)-one for use in therapy.
1-(((S)-7-((R)-3-Cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-4-phenyl-5-(piperazine-1-carbonyl)pyridin-2(1H)-one for use in a method of treating muscular atrophy.
1-(((S)-7-((R)-3-Cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-4-phenyl-5-(piperazine-1-carbonyl)pyridin-2(1H)-one for use in a method of treating obesity.
1-(((S)-7-((R)-3-Cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-4-phenyl-5-(piperazine-1-carbonyl)pyridin-2(1H)-one for use in a method of treating insulin resistance.
1-(((S)-7-((R)-3-Cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-4-phenyl-5-(piperazine-1-carbonyl)pyridin-2(1H)-one for use in a method of treating type II diabetes.
1-(((S)-7-((R)-3-Cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-4-phenyl-5-(piperazine-1-carbonyl)pyridin-2(1H)-one for use in a method of treating cachexia or sarcopenia.
A USP19 inhibitor for use in treating obesity.
A USP19 inhibitor for use in treating muscular atrophy.
A USP19 inhibitor for use in treating type II diabetes.
A USP19 inhibitor for use in treating insulin resistance.
A USP19 inhibitor for use in treating cancer.
A method of treating cancer, obesity, insulin resistance, type II diabetes and/or muscular atrophy comprising administering to a subject in need thereof an effective amount of a USP19 inhibitor.
Dependencies are inferred from the claim text.